Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Basliea

EU flag

Europe gains access to first stem cell drug

Chiesi's Holoclar has been given the green light for a rare eye condition

- PMLiVE

Advagraf shows survival increase for liver transplant patients

Astellas drug shows significant improvement in study published in the AJT

- PMLiVE

Astellas joins trial data sharing website

Joins Bayer, Boehringer, GSK, Lilly, Novartis, Roche and more

- PMLiVE

Imbruvica gets FDA OK for rare lymphoma

Cancer drug available in US to treat Waldenström's macroglobulinaemia          

- PMLiVE

NICE backs first ‘ultra-orphan’ drug Soliris

Final guidance backs Alexion’s treatment for very rare blood clot condition

- PMLiVE

FDA panel backs new antifungal Cresemba

Basilea/Astellas drug tipped to become a $500m product

- PMLiVE

Eric Terhaerdt leaves AZ for Astellas

Joins as senior VP of global development operations

- PMLiVE

Boehringer drug approved in EU for rare lung disease

Nintedanib is already available as cancer treatment

Shire Basingstoke

Shire signs deal to buy NPS for $5.2bn

Firm hopes to boost its presence in rare disease sector

Astellas forges $675m muscle alliance with Cytokinetics

Extendscollaboration to include neuromuscular diseases

- PMLiVE

Assessing drugs for ultra-rare conditions in the UK

Alexion’s Soliris has become the first drug to pass through NICE’s new highly specialised technology process

- PMLiVE

FDA approves Ipsen drug to treat rare tumours

Green light for Somatuline Depot in cancer of the neuroendocrine system

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links